MRG 001 - MedRegen
Alternative Names: MRG-001 - MedRegenLatest Information Update: 25 Mar 2024
Price :
$50 *
At a glance
- Originator MedRegen
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 21 Mar 2024 MedRegen plans a phase II trial for Amyotrophic lateral sclerosis (SC, Injection) in July 2024 (NCT06315608)
- 13 Mar 2024 MedRegen plans a phase IIa SUMMIT trial for Adult respiratory distress syndrome (SC, Injection) in July 2024 (NCT06308926)
- 13 Mar 2024 MedRegen plans a phase II trial for Alcoholic hepatitis (SC) in September 2024 (NCT06307522)